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Xiaojing Xu1†, Peixin Huang1†, Biwei Yang1, Xiangdong Wang2* and Jinglin Xia1*Abstract
Inflammatory factors play a vital role in the progression of liver cancer, although exact factors and related
mechanisms still remain unclear. The present study aimed at screening inflammatory factors related to liver cancer
metastasis and investigating the potential mechanism by which cancer cells are recruited. We screened and
validated inflammatory factors by microarray and RT-PCR. Small interfering RNA (siRNA) and recombinant protein
were used to assess CXCL5 effects on the movement of liver cancer cells (LCCs). Our screening microarray
demonstrated over-expression of CXCL5 in LCCs with high metastatic potentials. CXCL5 increased LCCs migration
and invasion, probably through autocrine and paracrine mechanisms. CXCL5-CXCR2 and ERK1/2 pathways could
play critical roles in the regulation of LCCs migration. Our data indicates that LCCs per se may act as the producer
and receptor of CXCL5 responsible for liver cancer migration and invasion.
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Primary liver cancer is the fifth most common malig-
nancy and the third commonest cause of cancer mortal-
ity [1,2]. Metastasis is one of the main characteristics of
primary liver cancer, contributing to a poor 5-year sur-
vival rate (<9%) [3]. Inflammatory factors were proposed
to play an important role in the metastasis of liver can-
cer cells (LCCs) [4,5]. Cancer cells could produce a var-
iety of inflammatory factors to chemo-attract leukocytes
from the circulation to tumor tissues [6,7]. Recruited
leukocytes or activated cancer cells could further release
inflammatory mediators to regulate tumor metastasis, al-
though the exact factors and related mechanisms remain
unclear.
Chemotaxis of cancer cells and stromal cells in the
microenvironment is an essential component of tumor
dissemination during metastasis. Epithelial neutrophil-
activating peptide-78 (ENA-78/CXCL5) is a CXC chemo-
kine with presence of ELR motif at the NH2 terminus.
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unless otherwise stated.mediators of tumorigenesis in a number of cancers [8] and
CXCL5 was also found over-expressed in many types of
cancers, including liver cancer, mediating neutrophil infil-
tration and indicating poor prognosis [9-13]. However,
further studies about the role of CXCL5 on the recruit-
ment of liver cancer cells are still necessary.
The present study aimed at screening inflammatory
factors related with metastasis of liver cancer and inves-
tigating the potential mechanism by which they were in-
volved in cancer cell recruitment. We initially selected
epithelial CXCL5 as the target from gene mapping result
to investigate its chemo-attractive roles in the tumor cell
recruitment. Furthermore, the CXCL5-CXCR2-ERK sig-
naling pathway in LCCs was also monitored.Methods
Reagents
Human CXCL5/ENA-78 quantikine enzyme-linked im-
munosorbent assay (ELISA) kit (DX000), recombinant
human CXCL5/ENA-78, and anti-CXCR2/CXCL8RB and
anti-CXCL5 were purchased from R&D (Minneapolis,
MN, USA). SYBR Premix Ex Taq was from TaKaRa (Shiga,
Japan). Matrigel™ Basement Membrane Matrix was from
BD Bioscience (Franklin Lakes, NJ, and USA). Lipofecta-
mine™ 2000 Transfection Reagent was from InvitrogenThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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phospho-p44/42 MAPK(Erk1/2) (Thr202/Tyr204), anti-p38
MAPK, anti–phospho-p38 MAPK (Thr180/Tyr182), anti-
SAPK/JNK, anti–phospho-SAPK/JNK (Thr183/Tyr185), and
ERK1/2 inhibitor U0126 were from Cell Signaling Technol-
ogy (Boston, MA, USA). CXCR2 inhibitor SB225002 was ob-
tained from Calbiochem (Darmstadt, Germany).
Cell lines
Our institute established human LCCs with high me-
tastatic capacity (HCCLM3, MHCC97H and MHCC97L)
[14,15] with seeding density of 2 × 104/cm2. LCCs with
low metastatic capacity (SMCC7721, HepG2) were from
ATCC cell bank, and the seeding density was 4 × 103/cm2.
Cells were grown in Dulbecco's modified Eagle's medium
or RPMI-1640 supplemented with 10% fetal bovine serum
(FBS, Hyclone) at 37°C in a 5% CO2, 95% air environment
in humidified incubators.
When the cell density grew to 80-90%, mRNA and
cell supernatant were collected for RT-PCR and ELISA
respectively.
Mapping of inflammatory genes
Expressions of inflammatory genes were evaluated by the
human RT2Profiler PCR Inflammatory Cytokines and
Receptors Array (catalog number: PAHS-011, SABiosciences).
Total RNA was isolated using TRIZOL™LS reagent (Invitro-
gen, Carlsbad, CA). Two micrograms of RNA were used
for cDNA synthesis with the RT2 First Strand Kit (SA-
Biosciences). The RT2Profiler array was probed according to
the manufacturer’s protocol using the Profiler PCR Array
System and SYBR Green/Fluorescein qPCR Master Mix
(SABiosciences) in an ABI 7900 sequence analyzer (Applied
Biosystems). Gene expressions were compared with the dedi-
cated Web-based software package (http://pcrdataanalysis.
sabiosciences.com/pcr/arrayanalysis.php), which automatically
performs all 2-ΔCt based fold-change calculations from the
specific uploaded raw threshold cycle data [ΔCt =Ct
(inflammatory genes) - Ct (beta-actin)]. Differential expres-
sion values were identified using analysis of variance and/or
Student t test with a significance value of P< 0.05 and a
fold-change cut-off of 2-fold.
Measurement of mRNA expression
RNA isolation was performed using the TRIZOL™LS
reagent (Invitrogen, Carlsbad, CA). The cDNA was pre-
pared using an oligo (dT) primer (Additional file 1: Table
S1, not shown) and reverse transcriptase (Takara, Shiga,
Japan) following standard protocols. Quantitative real time
polymerase chain reaction (qRT-PCR) was performed
using SYBR Green on the ABI 7500 real-time PCR System
(Applied Biosystems, Foster City, CA). Each PCR reaction
mixture contained 10 μM of each primer, 10 μl of 2 ×
SYBR Green Premix Ex Taq, 1.6 μl cDNA and RNase-freewater, with a total volume of 20 μl. The PCR reaction was
carried out with a denaturation step at 95°C for 10 mins,
then 45 cycles at 95°C for 10 sec and finally at 60°C for
20 sec. All PCRs were performed in triplicate and norma-
lized to internal control beta-actin mRNA. Relative
expression was presented using the 2-ΔCt method [ΔCt =
Ct (chemokine) - Ct (beta-actin)].
Measurements of CXCL5 production
Levels of CXCL5 protein in the cell supernatant were
determined using ELISA in accordance with the protocol
provided by the manufacturer. Briefly, samples and stan-
dards were added in a 96 well polystyrene microplate
coated with CXCL5 primary antibody and incubated for
2 hrs. The plates were washed, added with CXCL5 con-
jugate antibody, and incubated for 2 hrs. The substrate
solution was added for color development after washing
twice, and the reaction was terminated with stop solu-
tion. Absorbance was measured at 450 nm. The final cell
number was counted and the amount of protein secreted
by 103 cells was used to represent the expression levels
of various cells.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde for 30 minutes
and permeabilized with wash buffer with 0.5% Triton X-
100 and 0.01% sodium azide. Cells were blocked with 1%
bovine serum albumin for 30 minutes, incubated in
CXCR2 primary antibody or PBS as controls overnight,
and then incubated with secondary antibody after wa-
shing thrice. Diaminobenzidine was added and incubated
for 5 minutes. Slips were stained with hematoxylin and
placed with mounting medium and scanned with an
Olympus confocal microscope (at 200× magnification).
Small interfering RNA transfection
Small interfering RNA (siRNA) transfections were
performed, according to the manufacturer’s protocol, in 6-
well plates using Lipofectamine™ 2000 with three different
sequences of siRNA (Additional file 1: Table S1) duplexes
targeting CXCL5 and a double-stranded RNA negative
control (GenePharma, Shanghai, China). Three μl of Lipo-
fectamine™ 2000 and 60 pmol of each siRNA were trans-
fected in triplicate, except for ratio-dependent effect
studies where several ratios of Lipofectamine™ 2000/siRNA
were tested to optimize the efficacy of transfection. Cells
were prepared for quantitative RT-PCR and ELISA
analyses either 48 hrs or 72 hrs after transfection.
Western blot
Protein samples (50 μg) were mixed with one-fourth
volume of SDS sample buffer, boiled for 5 mins, and then
separated through 10% SDS-PAGE gels. After electro-
phoresis, proteins were transferred to nylon membranes by
Table 1 qRT-PCR array (ratio) of inflammatory factors and
receptors between HCCLM3 and HepG2
Up-regulation Down-regulation
Gene Fold change Gene Fold change
CXCL12 2.3019 IL10RA 2.0307
IL13 2.3838 LTA 2.0895
IL36A 2.4158 ABCF1 2.197
IFNA2 3.2783 CXCL3 2.3116
CXCL8 3.4452 IL36G 2.6034
CARD18 4.2404 CXCL2 2.6868
IL1R1 5.9443 CXCL13 2.7931
TOLLIP 6.0692 RPL 2.809
CCL20 10.2342 CEBPB 3.1528
CCL15 10.7815 CCL5 3.1897
CCL26 13.5393 LTB4R 3.6407
CCL24 13.5841 B2M 3.8312
CXCL6 18.8126 IL-9 3.942
IL1RN 28.7457 TNF 4.9135
IL36B 34.1138 IL1A 5.7681
C5 114.9842 CXCL1 5.8887
CXCL5 1172.6051 CCL2 9.8094




Inflammatory factors & Receptors with fold change > 2 were shown.
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bovine serum albumin for 1 hr, rinsed and incubated with
primary antibodies in TBS diluted at 1:1000 at 4°C over-
night. Primary antibody was then removed by washing in
TBS-tween thrice, and labeled by incubating with 0.1 mg/
ml peroxidase-labeled secondary antibodies against the
mouse or rabbit for 1 hr. Bands were visualized by electro-
chemiluminescence and exposed to X-ray film following
washing thrice in TBS-tween.
Migration and invasion assay
Transwell chamber inserts (Corning Inc, Corning, NY) with
filter membrane pore size of 8 μm were coated with 80 μL
Matrigel (0.8 mg/mL, BD Bioscience, Mountain View, CA).
HepG2 and MHCC97H cells were incubated on the upper
chamber at the concentration of 5 × 105 /mL in serum-free
DMEM. DMEM containing 10% FBS was added to the
lower compartment with recombinant CXCL5 at final
concentrations of 0.1, 1.0, or 10 nM or with cell culture
supernatant after transfection. Cells migrated through the
permeable membrane during 48 hrs were fixed in para-
formaldehyde and stained with Giemsa. Cells in five micro-
scopic fields (at 200× magnification) were counted and
photographed. Each assay was done at least in triplicates.
Migration assays were applied similarly without coating the
upper chamber with Matrigel and migrated cells were
counted at 24 hrs. To investigate the role of CXCR2 or
ERK1/2 pathway, cells were pretreated with CXCR2 inhibi-
tor SB225002 at 5 or 10 μg/ml or ERK1/2 inhibitor U0126
at 5 or 10 μM for 2 hrs.
Wound-healing assay
GFP-HepG2 cells were seeded in 6-well plates and in-
cubated for 12 hrs. Two intersecting lines were scratched
by a sterilized pin to wipe off the adherent cells in
these lines to create a wound. SB225002 or U0126
were then added to the medium and a control was set
up with an equal concentration of DMSO. The migra-
tion of HepG2 was assessed using an inverted light
microscope at the original magnification X100 and
migrated distances of HepG2 were measured at 0, 24
or 48 hrs.
Statistical analysis
Data was expressed as mean ± standard errors. Statistical
comparisons of the results were made using analysis of
variance (ANOVA). Significant differences (P < 0.05)
between groups were analyzed by LSD test.
Results
Expression of inflammatory factors/receptors in LCCs
We measured the expression levels of 89 inflammatory
factors/receptors in HCCLM3 cells with high metastatic
capacity and HepG2 cells with low metastatic capacity.The results showed that 18 factors were up-regulated in
HCCLM3 including SPP1, CXCL5, C5, CXCL6, IL1RN,
while 21 were down-regulated including C3, CXCL11,
XCR1, CXCL10 (Table 1 and Additional file 2: Figure S1,
not shown). Six chemokines (CXCL1, CXCL3, CXCL5,
CXCL6, CCL2 and IL-1A) selected from the screening were
validated in five LCCs with different metastatic capacities
(in ascending order: HepG2, SMMC7721, MHCC97L,
MHCC97H and HCCLM3). Apart from CXCL3, levels of
CXCL1, CXCL5, CXCL6, CCL2 and IL-1A were consistent
with the results of qRT-PCR array. Levels of CXCL5 in
MHCC97L, MHCC97H and HCCLM3 cells were sig-
nificantly higher than those in HepG2 and SMMC7721
(Figure 1A). We further found that levels of CXCL5 pro-
tein in MHCC97L, MHCC97H or HCCLM3 were higher
than those from HepG2 or SMMC7721 through ELISA
and Western Blot (P <0.001, Figure 1B and D). Expression
of CXCR2 mRNA was high in HepG2 cells and medium
in MHCC97H and HCCLM3, but not in SMMC7721 and
MHCC97L (Figure 1C). Similar findings were noted in
the expression of CXCR2 protein by Western Blot and
immunocytochemistry (Figure 1D and E).
Figure 1 Expression of inflammatory factors/receptors in LCCs. A: Relative mRNA levels of CXCL1, CXCL3, CXCL5, CXCL6, CCL2 and IL-1A in
five LCCs by RT-PCR; B: Levels of CXCL5 protein in cell culture supernatant by ELISA (***P < 0.001); C: Relative mRNA levels of CXCR2 in five LCCs
by RT-PCR; D: Levels of CXCL5 and CXCR2 protein by Western Blot; E: Expression of CXCR2 protein by immunocytochemistry (×200).
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We assessed the role of CXCL5 by transfecting siRNA
into MHCC97H. The transfection efficiency was up to
70% with the ratio of Lipofectame2000 and siRNA at
1:20 (Figure 2A). Treatment with siRNA-277, siRNA-
313 or siRNA-445 could inhibit 73, 93 or 64% of CXCL5
mRNA expression and 48, 70 or 43% of CXCL5 protein
contents, respectively (Figure 2B). Cell migration and
invasion were significantly inhibited 72 hrs after the
transfection with siRNA-313 (P < 0.01, Figure 2C and D).
We also assessed the effect of recombinant CXCL5 on
the migration and invasion of HepG2 cells with high
amount of CXCR2 and low metastatic capacity. The
treatment with CXCL5 could increase the migration and
invasion of HepG2 in a dose-dependent manner (P <
0.05 or less, Figure 3A and B).Figure 2 Chemotaxis of CXCL5 on LCCs. A: Transfection efficiency with t
(A1), FAM (A2), and merged (A3) (×200); B: Inhibitory efficiency of three si
transfection measured by RT-PCR (B1) and protein levels of CXCL5 72hs aft
LCC migration and invasion measured by transwell assay (×200); D: Averag
(*P < 0.05, **P < 0.01, ***P < 0.001).Specificity of CXCL5/CXCR2
Treatment with CXCR2 inhibitor SB225002 at 5 or
10 μg/ml could inhibit CXCL5-induced migration and inva-
sion of HepG2 (Figure 3C). Migration and invasion of
SB225002-treated cells were significantly lower than in
CXCL5-stimulated cells (P < 0.01, respectively, Figure 3D).
This was also evidenced by the measurement of healing
percentage in Figure 3E. CXCL5 significantly increased the
migration of HepG2 cells at both 24 and 48 hrs, as compared
to controls, while the healing percentage of SB225002-
treated cells was significantly lower than that of cells stimu-
lated with CXCL5 (P < 0.01, respectively, Figure 3F).
Role of CXCL5-induced signal pathway
The phosphorylated and total amounts of p38 MAPK,
ERK1/2 or JNK were measured in HepG2 and MHCC97Hhe ratio of Lipofectame 2000 and siRNA at 1:20, including bright field
RNAs of CXCL5: relative mRNA levels of CXCL5 48hs after siRNA
er siRNA transfection measured by ELISA (B2); C: Effect of CXCL5 on
e cell numbers of migration and invasion in three identical experiments
Figure 3 (See legend on next page.)
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Figure 3 Chemotaxis of recombinant CXCL5 on LCCs and Specificity of CXCL5/CXCR2. A: Effect of recombinant CXCL5 on the migration
and invasion of HepG2 measured by transwell assay (×200); (B) Average cell numbers of migration and invasion in three identical experiments
(n = 3 each), HepG2 cells were incubated at the upper chamber and recombinant CXCL5 (0.1, 1.0, or 10 nM) was added into the lower
compartment; (C) Effect of CXCR2 inhibitor SB225002 on CXCL5-induced migration and invasion of HepG2 measured by transwell (×200);
(D) Average cell numbers of migration and invasion in three identical experiments (n = 3 each). (E) Effect of SB225002 on CXCL5-induced
migration and invasion of HepG2 measured by wound-healing assay (×100); (F) Levels of healing percent. (*P < 0.05, **P < 0.01, ***P < 0.001,
++P < 0.01, +++P < 0.001).
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with CXCL5 at 10 nM for 10, 20 or 30 mins (Figure 4A).
The amount of phosphorylated ERK1/2 increased stead-
ily with a peak at 20 mins after the treatment with CXCL5
in HepG2, but increased continuously in MHCC97H
(Figure 4B). The amount of phosphorylated p38 MAPK
increased in both cells by time, while the peak of in-
creased phosphorylated JNK was at 20 mins, as shown
in Figure 4B.
HepG2 cells were pre-incubated with the ERK1/2 in-
hibitor U0126 in transwells for 2 hrs, followed by the
stimulation of CXCL5 at 10 nM (Figure 4C) in order to
further evaluate the role of ERK1/2 signal pathway in
CXCL5-induced cell migration and invasion. U0126 at 5
or 10 μM significantly prevented CXCL5-induced cell mi-
gration and invasion in a dose-dependent pattern (P < 0.05
or less, Figure 4D). The inhibitory rates of U0126 at 5 and
10 μM were 32 and 66% in migration, and 46 and 74% in
invasion, respectively. The inhibitory effects of U0126 on
CXCL5-induced migration of HepG2 cells were further
evidenced by the measurement of the wound healing
percentage (Figure 4E). The healing percentage of cells
stimulated with CXCL5 was significantly higher than those
without stimulation, and significantly inhibited by U0126
at 24 and 48 hours (P < 0.01, Figure 4F).
Discussion
The present study mapped out the mRNA expression of
multiple inflammatory factors/receptors and demon-
strated that SPP1 and CXCL5 were highly over-expressed
in LCCs with high metastatic potentials. SSP1, also known
as osteopontin, has been well documented by our institute
as a promoter for hepatocellular carcinoma metastasis
[16]. CXCL5 was also suggested to serve as a novel
predictive marker for prognosis determination of many
cancers, such as colorectal cancer [12]. It is further evi-
denced by recent studies that CXCL5 was over-expressed
in HCC patients with shorter overall survival and high
tumor recurrence [9]. Therefore, the present study aimed
to provide more research about the important values and
roles of CXCL5 in LCC migration and invasion.
The present study demonstrated that CXC chemo-
kines with sequence Glu-Leu-Arg (ELR motif) were over-
expressed in LCCs with high metastatic potentials, such asCXCL12, CXCL5, and CXCL8. The ELR+CXC chemokines
have been proposed as important mediators of tumori-
genesis, angiogenesis, progression, and indicators of prog-
noses in a number of cancers [17-21]. Out of those, higher
expression and production of CXCL5 mRNA and protein
were found in cells with high metastatic potentials. CXCL5
could also increase the migration and invasion of CXCR2-
positive LCCs. Thus LCCs might act as the producer and
receptor of CXCL5 in the development and metastasis of
the cancer and may themselves play a critical role in the
initiation and formation of inflammatory microenviron-
ment like other cancer cells [22]. In addition, our data also
suggested both autocrine and paracrine mechanisms and
manners of CXCL5 in LCCs. CXCL5 could be produced by
liver cancer cells, but also by inflammatory cells (e.g. neu-
trophil, monocyte, macrophage) and structure cells (e.g.
epithelial, endothelial, fibroblastic) [8]. Autocrine and para-
crine CXCL5 may directly chemo-attract liver cancer cells
and circulating leukocytes for the development of an
inflammatory microenvironment.
CXCR2 [interleukin (IL)-8R] is a member of the G-
protein–coupled receptor superfamily, and the receptor of
ELR+CXC chemokines. CXCR2 expression in endothelial
cells is activated by ELR+CXC chemokines and promotes
tumor growth [23]. CXCR2 was also documented to be cor-
related with intrahepatic metastasis, portal cancer embolus
and TNM staging of liver cancer patients [20,24-27], al-
though the role of CXCR2 in tumor cells is debated. Ac-
tivated CXCR2 was found to promote cell proliferation,
migration, and invasion [28] and to assist cancer cells in
evading stress-induced apoptosis [29]. On the other hand,
the depletion of CXCR2 delays the replicative senescence
and impairs the senescence response to oncogenic signals
[30], suggesting that it acts as a tumor suppressor. However,
our results have shown that the expression of CXCR2 was
higher in HepG2 cells than that in MHCC97H and
HCCLM3, which indicated CXCR2 might be related to the
metastatic capacity of LCCs. However, the results do not
imply CXCR2 is a tumor suppressor, and further studies on
the role of CXCR2 per se will be summarized in our next
study. Notwithstanding its limitations, our results did indi-
cate that the certain expression of CXCR2 might be the
foundational requirement for LCC migration and invasion
when the concentration of CXCL5 in the environment was
Figure 4 (See legend on next page.)
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Figure 4 Activation of ERK1/2, p38and JNK induced by CXCL5 and role of ERK1/2 signal pathway in the chemotaxis of CXCL5 on LCCs.
(A) Phosphorylated and total amounts of ERK1/2, p38 MAPK or JNK measured by Western blot in HepG2 and MHCC97H; (B) Ratio of p-ERK1/2/
total ERK1/2, p-p38/total p38, p-JNK/total JNK in HepG2 and MHCC97H. (C) Effect of ERK1/2 inhibitor U0126 on CXCL5-induced migration and
invasion of HepG2 measured by transwell assay (×200); (D) Average cell numbers of migration and invasion in three identical experiments
(n = 3 each). (E) Effect of U0126 on CXCL5-induced migration and invasion of HepG2 measured by wound-healing assay (×100); (F) Levels of
healing percent. GFP-HepG2 cells were pretreated with or without U0126 at 10 μM or DMSO for 2hs, followed by challenge with or without
CXCL5 (controls) at 10 nM. (**P < 0.01, +P < 0.05, ++P < 0.01, +++P < 0.001).
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static potential is activated by CXCL5, and promotes the
migratory and invasive capacity of HepG2. Moreover, the
chemotaxis induced by CXCL5 is CXCR2-dependent,
evidenced by the inhibitory effects of SB225002. Thus, CXCL5-
CXCR2 may play an important role in LCCmetastasis.
Cancer invasion and metastasis is initiated and main-
tained by signaling pathways in the tumor microenviron-
ment, followed by cell migration into the adjacent tissue
[31,32]. Invasion- and migration-promoting chemokinesFigure 5 Roles of CXCL5 in the metastasis of liver cancer cells. CXCL5
and paracrine mechanism. CXCL5-CXCR2-ERK1/2 pathways could play critic
se act as the producer and receptor of CXCL5, responsible for the developm
of malignancy.and corresponding receptors mediate invasive migration of
tumor cells through a variety of pathways [33]. Our data
demonstrated that the activations of ERK1/2, p38 MAPK
and JNK pathways were involved in the regulation of
CXCL5-induced migration and invasion of LCCs. Of those,
the ERK1/2 signal pathway might play a more dominate
role in the movement of LCCs with CXCL5 stimulation,
evidenced by the finding that U0126 at 10 μM could
inhibit about 65 and 75% of CXCL5-induced cell migration
and invasion.increased LCCs migration and invasion, probably through autocrine
al and necessary roles in the regulation of LCCs migration. LCCs per
ent of inflammatory microenvironment and the promotion
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expression of CXCL5 in LCCs with high metastatic po-
tentials and that CXCL5 could increase LCC’s migration
and invasion, probably through autocrine and paracrine
mechanisms. Evidence also suggests that CXCL5-CXCR2-
ERK1/2 pathways might play critical roles in LCC migration
and invasion (Figure 5) and Additional file 3: Figure S2,
not shown).
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